These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35532338)

  • 1. Containing the spread of COVID-19 virus facing to its high mutation rate: approach to intervention using a nonspecific way of blocking its entry into the cells.
    Nguyen KV
    Nucleosides Nucleotides Nucleic Acids; 2022; 41(8):778-814. PubMed ID: 35532338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
    Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
    Elife; 2020 Oct; 9():. PubMed ID: 33103998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
    Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
    J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
    Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
    J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor.
    Nguyen KV
    Nucleosides Nucleotides Nucleic Acids; 2021; 40(6):665-706. PubMed ID: 33982646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues.
    Badawi S; Ali BR
    Hum Genomics; 2021 Jan; 15(1):8. PubMed ID: 33514423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
    Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
    Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic.
    Villa A; Brunialti E; Dellavedova J; Meda C; Rebecchi M; Conti M; Donnici L; De Francesco R; Reggiani A; Lionetti V; Ciana P
    Pharmacol Res; 2022 Jan; 175():105982. PubMed ID: 34798263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2.
    Suryamohan K; Diwanji D; Stawiski EW; Gupta R; Miersch S; Liu J; Chen C; Jiang YP; Fellouse FA; Sathirapongsasuti JF; Albers PK; Deepak T; Saberianfar R; Ratan A; Washburn G; Mis M; Santhosh D; Somasekar S; Hiranjith GH; Vargas D; Mohan S; Phalke S; Kuriakose B; Antony A; Ustav M; Schuster SC; Sidhu S; Junutula JR; Jura N; Seshagiri S
    Commun Biol; 2021 Apr; 4(1):475. PubMed ID: 33846513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation.
    Huang SW; Miller SO; Yen CH; Wang SF
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor.
    Capraz T; Kienzl NF; Laurent E; Perthold JW; Föderl-Höbenreich E; Grünwald-Gruber C; Maresch D; Monteil V; Niederhöfer J; Wirnsberger G; Mirazimi A; Zatloukal K; Mach L; Penninger JM; Oostenbrink C; Stadlmann J
    Elife; 2021 Dec; 10():. PubMed ID: 34927585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species.
    Zhang HL; Li YM; Sun J; Zhang YY; Wang TY; Sun MX; Wang MH; Yang YL; Hu XL; Tang YD; Zhao J; Cai X
    J Biol Chem; 2021; 296():100435. PubMed ID: 33610551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity.
    Ozono S; Zhang Y; Ode H; Sano K; Tan TS; Imai K; Miyoshi K; Kishigami S; Ueno T; Iwatani Y; Suzuki T; Tokunaga K
    Nat Commun; 2021 Feb; 12(1):848. PubMed ID: 33558493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.